Supernus Pharmaceuticals | SUPN - Assets


Supernus Pharmaceuticals reported $1.45B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Abbott USD 86.71B 2.53B Dec/2025
ANI Pharmaceuticals USD 1.44B 32.22M Dec/2025
Aurora Cannabis CAD 756.86M 80.98M Sep/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Canopy Growth CAD 1.07B 165.17M Sep/2025
Cara Therapeutics USD 43.75M 4.8M Jun/2025
Corcept Therapeutics USD 836.65M 13.04M Dec/2025
Eisai JPY 1.49T 48.22B Dec/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Novo Nordisk DKK 542.9B 30.61B Dec/2025
Pacira USD 1.26B 32.66M Dec/2025
Perrigo USD 8.54B 1.55B Dec/2025
Pfizer USD 208.73B 2.64B Sep/2025
Supernus Pharmaceuticals USD 1.45B 32.89M Dec/2025
United Therapeutics USD 7.88B 528.9M Dec/2025
Xeris Pharmaceuticals USD 370.19M 35.5M Sep/2025